FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, pharmacology and biology and concerns use of Trecresan as an acid phospholipase A1 modulator.
EFFECT: invention allows extending the range of acid phospholipase A1 modulators.
5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT TO DECREASE CHOLESTEROL ESTERASE ACTIVITY | 2010 |
|
RU2444357C1 |
| AGENT INTENSIFYING THROMBOCYTE ACID LYPASE ACTIVITY | 2010 |
|
RU2429833C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND BIS-(2-METHYLPHENOXY-ACETATE) ZINC (ZINCATRAN) FOR REDUCING TOTAL ACTIVITY OF ACIDIC PHOSPHOLIPASE A1 | 2014 |
|
RU2545888C1 |
| 1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
| METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
| USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
| METHOD OF ATHEROGENESIS CORRECTION IN EXPERIMENT USING 1-(GERMATRAN-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2741906C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
| TRECRESAN APPLICATION FOR TREATING PATIENTS SUFFERING ARTERIAL HYPERTENSION AND OBESITY | 2010 |
|
RU2429832C1 |
| SUBSTANCE REDUCING CHOLESTEROL ESTERASE ACTIVITY | 2014 |
|
RU2540518C1 |
